APR 2015 ARTICLE LIST >>
PharmaTutor (April- 2015)
Print-ISSN: 2394 - 6679
e-ISSN: 2347 - 7881
(Volume 3, Issue 4)
Received On: 05/02/2015; Accepted On: 18/02/2015; Published On: 01/04/2015
AUTHORS: Vinit Raj*, Amit Rai, Deepak Kumar, Vinod Kumar
Department of Pharmaceutical Sciences,
Babasaheb BhimraoAmbedkar University (A Central University),
Vidya Vihar, Raebreli Road, Lucknow, Uttar Pradesh, India
*raj.vinit24@gmail.com
ABSTRACT
Epilepsy is a common brain disease that is characterized by recurrent and spontaneous seizures that result from abnormal and excessive synchronization of neuronal activity. Whereas, accumulation of Ca++ in presynaptic terminals, leading to improved neurotransmitter release. In additional, depolarization-induced inauguration of the NMDA subtype of the excitatory amino acid receptor, which causes more Ca++ influx and neuronal activation. The main aim of this study to focus on the deactivation of Ca++ influx and prevent the augmentation of neuron activation. However, we performed molecular modeling of novel 1,3,4-thiadiazole derivatives keeping in view structural requirement of pharmacophore and Quantitative structure activity relationship (QSAR) and evaluated in silico anticonvulsant activity. Docking procedures allow virtually screening a database of compounds and predict the strongest binder based on various scoring functions. In the docking study, targeted ligand produced significantly affinity with the calcium channel receptor which is slightly higher than the phenytoin drug. A computational study was also carried out including prediction of pharmacokinetic properties, toxicity and bioactivity studies. All above parameter was calculated which exhibited slightly excellent compared than standard Phenytoin drug. The above observation suggested that these compounds would serve as better lead for anticonvulsant screening for future drug design perspective.
How to cite this article: V Raj, A Rai, D Kumar, V Kumar; Molecular Modeling Studied for Inhibition of Calcium Channel Receptor: A Strategy for the development of new Antiepileptic Drug; PharmaTutor; 2015; 3(4); 33-39
[ABSTRACT WITH CITATION] [VIEW AS HTML]
REFERENCES:
1. McNamara OJ.; Drugs effective in the therapy of the Epilepsys in: Hardman JG, Gilman(Eds) LC; The Pharmacological basis of therapeutical; McGraw-Hill; New York; 2001; 521-548.
2. Loscher W. New visions in the pharmacology of anticonvulsion; Eur.J. Pharmacol.; 1998; 342:1e13.
3. Chang BS, and Lowenstein DH. Epilepsy. N. Engl. J. Med, 2003, 349 (13): 1257-1266.
4. Schmidt D and Stavem K.; Long-term seizure outcome of surgery versus no surgery for drug-resistant partial epilepsy: a review of controlled studies; Epilepsia; 2009; 50; 1301.
5. Perucca E, Bialer M.The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on, topiramatezonisamide and tiagabine. ClinPharmacokinet; 1996; 31; 29–46.
6. Zhaiwei Lin, Pankaja K Kadab. Molecular targets for the rational design of antiepileptic drugs and related neuroprotective agents. Med. Res. Rev; 1997; 17(6); 537-572.
7. Pandeya SN, Raja AS, Stables JP; Synthesis of isatinsemicarbazones as novel anticonvulsants-role of hydrogen bonding; J. Pharm Pharm Sci.;2002; 5(3);266-71.
8. Can ÖD, Altlntop MD, Özkay ÜD, Üçel UI, Ruer BD and Kaplanclkl ZA; Synthesis of Thiadiazole Derivatives Bearing Hydrazone Moieties and Evaluation of Their Pharmacological Effects on Anxiety, Depression, and Nociception Parameters in Mice; Arch Pharm Res; 2012; 35(4): 659-669.
9. Demirbas N, Karaoglu SA and Sancak K; Synthesis and antimicrobial activities of some new 1- (5-phenylamino- [1, 3, 4]thiadiazole-2-yl)methyl-5-oxo-[1, 2, 4]triazole and 1-(4-phenyl-5-thioxo-[1, 2, 4] triazole-3-yl)methyl-5- oxo-[1, 2, 4]triazole derivatives; Eur J Med Chem; 2004; 39; 793-804.
10. Karegoudar P, Jagdeesh Prasad D, Ashok M, Mahalinga M, Poojary B, Shivarama Holla B; Synthesis, Antimicrobial And Anti-Inflammatory Activities Of Some 1, 2, 4-Triazolo[3, 4-B][1, 3, 4]Thiadiazoles And 1, 2, 4- Triazolo [3, 4-B][1, 3, 4] Thiadiazines Bearing Trichlorophenyl Moiety; european. Journal of Medicinal Chemistry; 2008; 43; 808-815.
11. Chou Y, Lais Y, Pan L, Jow M, Chen W and Guh H; Investigation of anticancer mechanisms of thiadiazolebased compound in human non-small cell lung cancer A 549; cells. Biochemist. Pharmacology; 2003; 66; 115-124
12. Cleici F, Pocar D, Guido M, Loch A, Perlini V and Brufani M; Synthesis of 2-amino-5-sulfanyl-1, 3, 4-thiadiazole derivatives and evaluation of their antidepressant and anxiolytic activity; J Med Chem; 2001; 44 (6); 931-936.
13. Martinez A, Alonso D, Castro A, Aran J, Cardelus I and Banos E; Synthesis and Potential muscarinic receptor binding and antioxidant properties of 3-(thiadiazolyl) pyridine 1-oxide compounds; Arch Pharm; 1999; 332; 191- 194.
14. Mohammad Y, Riaz AK, Khan M and Ahmed B; An Interactive Human Carbonic Anhydrase-II (hCAII) Receptor–Pharmacophore Molecular Model & Anti-Convulsant Activity of the Designed and Synthesized 5- Amino-1,3,4-Thiadiazole-2-Thiol Conjugated Imine Derivatives; ChemBiol Drug Des; 2013; 81; 666–673.
15. Shankar GA, Kallanagouda R. Alagawadi, Pranali V. Sonkusare, Sagar M. Chaudhary, Dilip H. Dadwe, Amol S. Shah; Novel imidazo [2, 1-b][1, 3, 4] thiadiazole carrying rhodanine-3-acetic acid as potential antitubercular agents; Bioorganic & Medicinal Chemistry Letters; 2012; 22; 1917–1921.
16. Oruc E, Rollas S, Kandemirli F, Shvets N and Dimoglo A; 1, 3, 4-thiadiazole derivatives, synthesis, structure elucidation and structure antituberculosis activity relationship investigation; J Med Chem; 2004; 47; 6760-6767.
17. Srivastava V, Kumar A; Molecular docking studies on DMDP derivatives as human DHFR inhibitors; Bioinformation; 2008; 3(4); 180-188.
18. Molinspiration Cheminformatics, Bratislava, Slovak Republic; Available from: http://www.molinspiration.com/ services/properties.html [accessed 16.08.2010].
19. Zhao Y, Abraham MH, Lee J, Hersey A, Luscombe NC, Beck G, Sherborne BI; Rate-limited steps of human oral absorption and QSAR studies; Pharm. Res; 2002;19; 1446–1456.
.png)
